Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma
Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma
复制标题
DOI：
10.1111/vox.12158
复制
发表时间：
2014-10-01
期刊：
影响因子：
2.7
通讯作者：
Lee, S. W.
中科院分区：
文献类型：
--
作者：
Kwon, S. Y.;Kim, I. S.;Lee, S. W.
背景和目的本研究旨在评价Mirasol PRT系统和Intercept Blood System.Methods对悬浮在血浆中的非白细胞减少的富含血小板的血浆衍生血小板进行病原体灭活（PI）的效果。使用每种病毒株的四份重复样品进行评价。对于细菌，使用低滴度（45-152 CFU/单位）接种和高滴度（7.34-10.18 log CFU/单位）接种，每种细菌菌株重复两次。结果Mirasol和Intercept系统对病毒的灭活效果分别为：人类免疫缺陷病毒1型>= 4.19 vs. >= 4.23;牛病毒性腹泻病毒，1.83 vs. >= 6.03;伪狂犬病病毒，2.73 vs. >= 5.20;甲型肝炎病毒，0.62 vs. 0.76;猪细小病毒，0.28 vs. 0.38。对细菌的灭活效果如下：大肠杆菌，5.45 vs. >= 9.22;金黄色葡萄球菌，4.26 vs. >= 10.11;枯草芽孢杆菌，5.09 vs. >= 7.74。低滴度S.金黄色葡萄球菌或B。结论Intercept对包膜病毒的灭活效果较好。Mirasol仅对HIV-1表现出令人满意的灭活效果。两种系统均未灭活两种选定的无包膜病毒。Intercept的灭活效力对于高或低滴度下检测的所有细菌更稳健。
Background and Objectives This study was conducted to evaluate the efficacy of pathogen inactivation (PI) in non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma using the Mirasol PRT System and the Intercept Blood System.Methods Platelets were pooled using the Acrodose PL system and separated into two aliquots for Mirasol and Intercept treatment. Four replicates of each viral strain were used for the evaluation. For bacteria, both low-titre (45-152 CFU/unit) inoculation and high-titre (7.34-10.18 log CFU/unit) inoculation with two replicates for each bacterial strain were used. Platelets with non-detectable bacterial growth and platelets inoculated with a low titre were stored for 5 days, and culture was performed with the BacT/ALERT system.Results The inactivation efficacy expressed as log reduction for Mirasol and Intercept systems for viruses was as follows: human immunodeficiency virus 1, >= 4.19 vs. >= 4.23; bovine viral diarrhoea virus, 1.83 vs. >= 6.03; pseudorabies virus, 2.73 vs. >= 5.20; hepatitis A virus, 0.62 vs. 0.76; and porcine parvovirus, 0.28 vs. 0.38. The inactivation efficacy for bacteria was as follows: Escherichia coli, 5.45 vs. >= 9.22; Staphylococcus aureus, 4.26 vs. >= 10.11; and Bacillus subtilis, 5.09 vs. >= 7.74. Postinactivation bacterial growth in platelets inoculated with a low titre of S. aureus or B. subtilis was detected only with Mirasol.Conclusion Pathogen inactivation efficacy of Intercept for enveloped viruses was found to be satisfactory. Mirasol showed satisfactory inactivation efficacy for HIV-1 only. The two selected non-enveloped viruses were not inactivated by both systems. Inactivation efficacy of Intercept was more robust for all bacteria tested at high or low titres.